The Payline

What's in Every Issue

Four sections. Every issue. Consistently useful for researchers at every stage.

🔬

The Insight

One deep-dive into reviewer psychology, study section dynamics, or a specific aspect of grant writing that most researchers get wrong. These are the things that separate triaged grants from funded ones — and we explain them clearly with real examples from funded and rejected applications.

📊

Grant Intelligence

Upcoming deadlines, new FOAs, IC-specific funding priorities, and payline updates from NIH. We monitor RePORTER, NIH Guide, and study section rosters so you do not have to. Includes a brief analysis of what new funding opportunities mean for your research area.

⚡

FrankGrant Update

New features, case studies from recent grant cycles (anonymized), and behind-the-scenes looks at how our Study Section simulation caught specific weaknesses. Includes data from our funded grant cohort — what approaches worked, what did not, and what we learned.

❓

One Question Answered

Each issue, we take a real question from a subscriber and answer it in depth. Questions like "Should I submit to NCI or NIDDK for my metabolic oncology research?" or "How do I handle a reviewer who misunderstood my innovation claim?" — answered honestly and completely.

Sample Issue

Here is what a typical Payline issue looks like.

The Payline · Issue #14 · March 2026

Why "Novel" Is the Most Dangerous Word in Your Innovation Section

The Insight

Why "Novel" Is the Most Dangerous Word in Your Innovation Section

Reviewers see "novel" more than any other word in Innovation sections — and it has lost almost all meaning. In an analysis of 47 Summary Statements from funded and unfunded SBIR Phase I grants across NCI and NIDDK study sections, grants that led with "novel" in their Innovation section scored an average of 4.2 points lower on the Innovation criterion than those that led with a specific mechanistic claim. Here is what to write instead...

Grant Intelligence

NCI Payline Update: Standard pool at 11th percentile for R01s

NCI has announced that the R01 standard payline for fiscal year 2026 is at the 11th percentile for both new and renewal applications, down from the 13th percentile last year. SBIR Phase I paylines remain at the 35th percentile. Three new PARs relevant to immuno-oncology and early detection have opened this cycle...

One Question Answered

Q: My reviewer said my sample size was too small but I followed the FOA guidelines — what do I do for the resubmission?

This is more common than you might think, and it reveals an important truth about NIH review: reviewer concerns often reflect their personal experience more than the objective requirements of the FOA. Here is how to address this in your Introduction to Resubmission without appearing defensive...